일 정신병원 외래환자 대상 항정신성 장기지속형주사제 최근 10년간 약물 사용 현황
Drug Use Pattern of Long-Acting Injectable Antipsychotics on Outpatient of National Mental Hospital During the Last 10 Years
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : Atypical long-acting injectable antipsychotics (LAIA) have been used on psychiatry patients since 2003 to solve drug lowing adherence. However, prior studies on drug patterns and trends are lacking. The purpose of this study was to offer base data of pharmacotherapy by analyzing the trends or characteristics of each long-acting injection (LAI). Methods : Prescription data were collected by electronic medical record on outpatient of the psychiatry department of a National Mental Hospital 2011 to 2020. Total 4,292 LAIs prescriptions were obtained and analyzed retrospectively on sex, age, medical insurance, diagnosis, concomitant drugs by χ2 test and frequency analysis. Results : LAIA were increased during the last 10 years (P<0.001). Those were increased on age for 18-34 (P=0.018) and age 35-64 (P=0.009) and decreased on older than age 65 (P<0.001), and no difference on sex (P=0.136). Significantly, prescription rate of each LAI was different from sex, age, health insurance. Each LAI was used higher in schizophrenia while aripiprazole LAIs were used in bipolar (P<0.001). Concomitant drug rate was 59.5%. Aripiprazole LAIs (37.1%), risperidone LAIs (55.4%) were prescribed at monotherapy. The number of concomitant drug was 1.50±1.825 in polypharmacy. Each LAI showed significant difference in the frequency of use of the concomitant drug efficacy group, antipsychotics were used the most. LAIs used a variety of 115 concomitant drugs. Conclusion : The use of LAIA increased, and LAIs were used with a variety of drugs. If pharmacists review the drug interaction of LAIs and offer detailed explanations, they can serve to reduce spontaneous discontinuation and to improve compliance of LAIs.
Abstract
Background : Atypical long-acting injectable antipsychotics (LAIA) have been used on psychiatry patients since 2003 to solve drug lowing adherence. However, prior studies on drug patterns and trends are lacking. The purpose of this study was to offer base data of pharmacotherapy by analyzing the trends or characteristics of each long-acting injection (LAI). Methods : Prescription data were collected by electronic medical record on outpatient of the psychiatry department of a National Mental Hospital 2011 to 2020. Total 4,292 LAIs prescriptions were obtained and analyzed retrospectively on sex, age, medical insurance, diagnosis, concomitant drugs by χ2 test and frequency analysis. Results : LAIA were increased during the last 10 years (P<0.001). Those were increased on age for 18-34 (P=0.018) and age 35-64 (P=0.009) and decreased on older than age 65 (P<0.001), and no difference on sex (P=0.136). Significantly, prescription rate of each LAI was different from sex, age, health insurance. Each LAI was used higher in schizophrenia while aripiprazole LAIs were used in bipolar (P<0.001). Concomitant drug rate was 59.5%. Aripiprazole LAIs (37.1%), risperidone LAIs (55.4%) were prescribed at monotherapy. The number of concomitant drug was 1.50±1.825 in polypharmacy. Each LAI showed significant difference in the frequency of use of the concomitant drug efficacy group, antipsychotics were used the most. LAIs used a variety of 115 concomitant drugs. Conclusion : The use of LAIA increased, and LAIs were used with a variety of drugs. If pharmacists review the drug interaction of LAIs and offer detailed explanations, they can serve to reduce spontaneous discontinuation and to improve compliance of LAIs.
참고문헌 (21)
- 김하린, "팔리페리돈 장기지속형주사제의 약물 순응도와 치료 효과", 신경정신의학, 54(1), pp.69~75 (2015), 대한신경정신의학회[DOI]
- 이원경, "약물치료에 대한 순응도의 평가와 개선", 대한의사협회지, 64(2), pp.130~136 (2021), 대한의사협회[DOI]
- Lambert M, "Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis", J Clin Psychopharmacol, 30(5), pp.565~572 (2010)
- Velligan DI, "The expert consensus guideline series : adherence problems in patients with serious and persistent mental illness", J Clin Psychiatry, 70, pp.1~48 (2009)
- "Online Drug Library" (2018)[URL]
- Kim YS, "Principle and practice of long acting injectable antipsychotics", pp.19~ (2012), Seoul national university press
- Julius RJ, "Medication adherence : a review of the literature and implications for clinical practice", J Psychiatr Pract, 15(1), pp.34~44 (2009)
- Kishimoto T, "Long acting injectable versus oral antipsychotics in schizophrenia : a systemetic review and meta analysis of mirror-image studies", J Clin Psychiatry, 74(10), pp.957~965 (2013)
- Gopal S, "Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia : a randomized, double blind, placebo-controlled, dose-response study", Int Clin psychopharmacol, 25(5), pp.247~256 (2010)
- Kramer M, "Paliperidone palmitate, a potential long acting treatment for patients with schizophrenia. Results of a randomized, double blind, placebo-controlled efficacy and safety study", Int J Neuropsychopharmacol, 13(5), pp.635~647 (2010)
- Gaviria AM, "Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Spanish Province of Tarragona Catchment Area", Prim Care Companion CNS Disord, 19(2) (2017)
- Janzen D, "Trends in The Use of Long-Acting Injectable Antipsychotics in the Province of Manitoba, Canada", J Clin Psychopharmacol, 40(1), pp.6~13 (2020)
- Veehof L, "The development of polypharmacy. A longitudinal study", Fam Pract, 17(3), pp.261~267 (2000)
- Toto S, "Psychopharmacological Treatment of Schizophrenia Over Time in 30908 Inpatients : Data From the AMSP Study", Int J Neuropsychopharmacol, 22(9), pp.560~573 (2019)
- Patel MX, "Antipsychotic long acting injections : Mind the gap", British J Psychiatry, 52, pp.1~4 (2009)
- Tang CT, "Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region", Asia Pac Psychiatry, 12(4), pp.e12393~ (2020)
- Cynthia A, "Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014", Psychiatric Services, 69(9), pp.1015~1020 (2018)
- Olayinka O, "Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital", Psychiatry J, 2019, pp.1~5 (2019)
- "국립나주병원 외래 환자의 약물사용현황 분석. 2019년도 국립나주병원 임상연구논문집" (2020)[URL]
- Cordiner M, "Effectiveness of long-acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate", Ther Adv Psychopharmacol, 6(2), pp.66~76 (2016)
- Shuichi S, "Characteristics of people on long-acting injectable antipsychotics in Australia : Data from the 2010 National Survey of High Impact Psychosis", Australian &New Zealand J Psychiatry, 55(10), pp.958~975 (2021)